Novartis winds down ph. 1 solid tumor program after lacking efficacy
Novartis winds down ph. 1 solid tumor program after lacking efficacy
Body unavailable. Use the original source.
Novartis winds down ph. 1 solid tumor program after lacking efficacy
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.